MA43377A - Méthodes et compositions liées à la toxicité associée à la thérapie cellulaire - Google Patents

Méthodes et compositions liées à la toxicité associée à la thérapie cellulaire

Info

Publication number
MA43377A
MA43377A MA043377A MA43377A MA43377A MA 43377 A MA43377 A MA 43377A MA 043377 A MA043377 A MA 043377A MA 43377 A MA43377 A MA 43377A MA 43377 A MA43377 A MA 43377A
Authority
MA
Morocco
Prior art keywords
methods
cell therapy
toxicity associated
compositions related
compositions
Prior art date
Application number
MA043377A
Other languages
English (en)
Inventor
Mark J Gilbert
He Li
David Maloney
Stanley R Riddell
Cameron J Turtle
Original Assignee
Hutchinson Fred Cancer Res
Juno Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hutchinson Fred Cancer Res, Juno Therapeutics Inc filed Critical Hutchinson Fred Cancer Res
Publication of MA43377A publication Critical patent/MA43377A/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464411—Immunoglobulin superfamily
    • A61K39/464412—CD19 or B4
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6866—Interferon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
MA043377A 2015-12-04 2016-12-02 Méthodes et compositions liées à la toxicité associée à la thérapie cellulaire MA43377A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562263612P 2015-12-04 2015-12-04
US201662417284P 2016-11-03 2016-11-03

Publications (1)

Publication Number Publication Date
MA43377A true MA43377A (fr) 2021-05-19

Family

ID=57737968

Family Applications (1)

Application Number Title Priority Date Filing Date
MA043377A MA43377A (fr) 2015-12-04 2016-12-02 Méthodes et compositions liées à la toxicité associée à la thérapie cellulaire

Country Status (5)

Country Link
US (2) US11815514B2 (fr)
EP (2) EP4012415A3 (fr)
ES (1) ES2901795T3 (fr)
MA (1) MA43377A (fr)
WO (1) WO2017096331A1 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170068504A (ko) 2014-10-08 2017-06-19 노파르티스 아게 키메라 항원 수용체 요법에 대한 치료 반응성을 예측하는 바이오마커 및 그의 용도
EP3932950A1 (fr) 2014-10-20 2022-01-05 Juno Therapeutics, Inc. Procédés et compositions pour dosage en thérapie cellulaire adoptive
EP3344996A2 (fr) 2015-09-03 2018-07-11 The Trustees Of The University Of Pennsylvania Biomarqueurs prédictifs du syndrome de libération de cytokines
AU2017295886C1 (en) * 2016-07-15 2024-01-25 Novartis Ag Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
CA3052474A1 (fr) * 2017-02-09 2018-08-16 Fred Hutchinson Cancer Research Center Biomarqueurs et leurs utilisations permettant la selection d'une intervention d'immunotherapie
CA3065120A1 (fr) 2017-06-02 2018-12-06 Juno Therapeutics, Inc. Articles de fabrication et procedes de traitement utilisant une therapie cellulaire adoptive
KR102557834B1 (ko) 2017-06-07 2023-07-21 프레시전 인코포레이티드 신규의 세포 태그의 발현
JP2020533962A (ja) * 2017-08-11 2020-11-26 フレッド ハッチンソン キャンサー リサーチ センター Ｂｒａｆ特異的ｔｃｒおよびその使用
US10899831B2 (en) 2017-10-02 2021-01-26 Humanigen, Inc. Method of reducing the level of non-GM-CSF cytokines/chemokines in immunotherapy-related toxicity
US11130805B2 (en) 2017-10-02 2021-09-28 Humanigen, Inc. Methods of treating CART-T cell therapy-induced neuroinflammation using a GM-CSF antagonist
US10870703B2 (en) 2017-10-02 2020-12-22 Humanigen, Inc. Methods of treating immunotherapy-related toxicity using a GM-CSF antagonist
US10927168B2 (en) 2017-10-02 2021-02-23 Humanicen, Inc. Method of reducing tumor relapse rate in immunotherapy by administration of lenzilumab
KR20200075851A (ko) * 2017-10-19 2020-06-26 셀렉티스 개선된 면역 세포들 치료를 위한 nk 억제제들의 타겟인 유전자 통합
WO2019089848A1 (fr) * 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Procédés associés à une charge tumorale pour évaluer une réponse à une thérapie cellulaire
WO2019109053A1 (fr) * 2017-12-01 2019-06-06 Juno Therapeutics, Inc. Procédés de dosage et de modulation de cellules génétiquement modifiées
KR20200128043A (ko) 2018-02-16 2020-11-11 인사이트 코포레이션 사이토카인-관련 장애의 치료를 위한 jak1 경로 억제제
CA3116412A1 (fr) * 2018-10-31 2020-05-07 Humanigen, Inc. Substances et methodes pour le traitement du cancer
WO2021168375A1 (fr) * 2020-02-20 2021-08-26 Kite Pharma, Inc. Thérapie par lymphocytes t à récepteurs antigéniques chimériques
JP2023518814A (ja) * 2020-03-23 2023-05-08 ジェネンテック， インコーポレイテッド Ｃｏｖｉｄ－１９肺炎における、ｉｌ－６アンタゴニストに対する応答を予測するためのバイオマーカー
WO2022109340A1 (fr) * 2020-11-20 2022-05-27 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Profils de biomarqueurs cliniques immunomodulateurs et leurs utilisations
CA3204374A1 (fr) 2020-12-08 2022-06-16 Incyte Corporation Inhibiteurs de la voie jak1 destines au traitement du vitiligo
AR125827A1 (es) * 2021-05-11 2023-08-16 Janssen Biotech Inc Métodos para minimizar la neurotoxicidad asociada a la terapia con células t del receptor de antígeno quimérico (car)
US20230268031A1 (en) * 2021-07-30 2023-08-24 Kite Pharma, Inc. Monitoring and management of cell therapy-induced toxicities

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4452773A (en) 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4795698A (en) 1985-10-04 1989-01-03 Immunicon Corporation Magnetic-polymer particles
IN165717B (fr) 1986-08-07 1989-12-23 Battelle Memorial Institute
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
ES2067018T3 (es) 1988-12-28 1995-03-16 Stefan Miltenyi Procedimiento y materiales para la separacion en alto gradiente magnetico de materiales biologicos.
US5200084A (en) 1990-09-26 1993-04-06 Immunicon Corporation Apparatus and methods for magnetic separation
WO1992008796A1 (fr) 1990-11-13 1992-05-29 Immunex Corporation Genes de fusion selectionnables bifonctionnels
EP0672144A1 (fr) 1992-10-20 1995-09-20 Chiron Corporation Antagonistes du recepteur d'interleukine 6
CA2163427A1 (fr) 1993-05-21 1994-12-08 Stephen D. Lupton Genes hybrides bifonctionnels selectables, a base du gene de la cytosine desaminase (cd)
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
US7008624B1 (en) 1995-02-22 2006-03-07 Immunex Corporation Antagonists of interleukin-15
DE19608753C1 (de) 1996-03-06 1997-06-26 Medigene Gmbh Transduktionssystem und seine Verwendung
WO1997034634A1 (fr) 1996-03-20 1997-09-25 Sloan-Kettering Institute For Cancer Research Produits de recombinaison d'anticorps diriges contre le gd2, constitues d'un fragment variable (fv) a chaine simple
EP1109921A4 (fr) 1998-09-04 2002-08-28 Sloan Kettering Inst Cancer Recepteurs de fusion specifiques a l'antigene prostatique specifique membranaire et ses utilisations
WO2000023573A2 (fr) 1998-10-20 2000-04-27 City Of Hope Cellules modifiees specifiques a la molecule cd20 et utilisation de ces dernieres pour l'immunotherapie cellulaires des malignites cd20?+¿
AU2001265346A1 (en) 2000-06-02 2001-12-17 Memorial Sloan-Kettering Cancer Center Artificial antigen presenting cells and methods of use thereof
EP1334188B1 (fr) 2000-11-07 2006-08-30 City of Hope Cellules immunitaires specifiques a cd19 redirigees
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US20090257994A1 (en) 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
BRPI0314038B8 (pt) 2002-09-06 2021-05-25 Amgen Inc anticorpo humano isolado, molécula de ácido nucleico isolada, vetor, uso de um anticorpo, e, composição farmacêutica
US20050129671A1 (en) 2003-03-11 2005-06-16 City Of Hope Mammalian antigen-presenting T cells and bi-specific T cells
ATE531263T1 (de) 2006-09-22 2011-11-15 Pharmacyclics Inc Hemmer der bruton-tyrosinkinase
EP2141997B1 (fr) 2007-03-30 2012-10-31 Memorial Sloan-Kettering Cancer Center Expression constitutive de ligands costimulants sur des lymphocytes t transférés de manière adoptive
EP3338896A1 (fr) * 2007-12-07 2018-06-27 Miltenyi Biotec GmbH Systèmes et procédés de traitement d'échantillons
US8479118B2 (en) 2007-12-10 2013-07-02 Microsoft Corporation Switching search providers within a browser search box
US20120164718A1 (en) 2008-05-06 2012-06-28 Innovative Micro Technology Removable/disposable apparatus for MEMS particle sorting device
JP5173594B2 (ja) 2008-05-27 2013-04-03 キヤノン株式会社 管理装置、画像形成装置及びそれらの処理方法
DK3006459T3 (da) 2008-08-26 2021-12-06 Hope City Fremgangsmåde og sammensætninger til forbedring af t-cellers antitumoreffektorfunktion
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
EP2496698B1 (fr) 2009-11-03 2019-01-09 City of Hope Récepteur du facteur de croissance de l'épiderme tronqué (egfrt) pour la sélection de lymphocytes t transduits
CA2800913C (fr) 2010-06-03 2019-07-23 Pharmacyclics, Inc. Utilisation d'inhibiteurs de la tyrosine kinase de bruton (btk)
JP5947311B2 (ja) 2010-12-09 2016-07-06 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 癌を治療するためのキメラ抗原受容体改変ｔ細胞の使用
AU2012230780B2 (en) 2011-03-23 2016-10-27 Fred Hutchinson Cancer Center Method and compositions for cellular immunotherapy
US8398282B2 (en) 2011-05-12 2013-03-19 Delphi Technologies, Inc. Vehicle front lighting assembly and systems having a variable tint electrowetting element
JP6368243B2 (ja) 2011-11-11 2018-08-08 フレッド ハッチンソン キャンサー リサーチ センター がんのためのサイクリンａ１に標的化されたｔ細胞免疫療法
CA2861491C (fr) 2012-02-13 2020-08-25 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Recepteurs d'antigene chimeres bispecifiques et utilisations therapeutiques de ceux-ci
WO2013126726A1 (fr) 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Lymphocytes t doubles transgéniques comportant un car et un tcr, et leurs procédés d'utilisation
CA2872471C (fr) 2012-05-03 2022-11-22 Fred Hutchinson Cancer Research Center Recepteurs de lymphocyte t a affinite augmentee et procedes pour fabriquer ceux-ci
MA37711A1 (fr) 2012-06-04 2017-05-31 Pharmacyclics Inc Formes cristallines d'un inhibiteur de tyrosine kinase de bruton
LT3338794T (lt) 2012-07-13 2020-05-25 The Trustees Of The University Of Pennsylvania Car priešnavikinio aktyvumo toksiškumo reguliavimas
KR102135239B1 (ko) 2012-08-20 2020-07-17 프레드 헛친슨 켄서 리서치 센터 세포 면역요법을 위한 방법 및 조성물
ES2743738T3 (es) 2012-10-02 2020-02-20 Memorial Sloan Kettering Cancer Center Composiciones y métodos para inmunoterapia
DE112012007250T5 (de) 2012-12-20 2015-10-08 Mitsubishi Electric Corp. Fahrzeuginterne Vorrichtung und Programm
TWI654206B (zh) 2013-03-16 2019-03-21 諾華公司 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症
US9108442B2 (en) 2013-08-20 2015-08-18 Ricoh Company, Ltd. Image forming apparatus
US20170016913A1 (en) * 2014-03-13 2017-01-19 Oxford University Innovation Limited Methods and system for determining the disease status of a subject
WO2017165571A1 (fr) 2016-03-22 2017-09-28 Seattle Children's Hospital (dba Seattle Children's Research Institute) Procédés d'intervention précoce pour prévenir ou atténuer la toxicité
WO2018093591A1 (fr) 2016-11-03 2018-05-24 Juno Therapeutics, Inc. Polythérapie de thérapie cellulaire et d'inhibiteur de la microglie
CA3065120A1 (fr) 2017-06-02 2018-12-06 Juno Therapeutics, Inc. Articles de fabrication et procedes de traitement utilisant une therapie cellulaire adoptive

Also Published As

Publication number Publication date
ES2901795T3 (es) 2022-03-23
EP4012415A3 (fr) 2022-12-07
EP3384294A1 (fr) 2018-10-10
EP4012415A2 (fr) 2022-06-15
US11815514B2 (en) 2023-11-14
WO2017096331A1 (fr) 2017-06-08
EP3384294B1 (fr) 2021-10-13
US20240103012A1 (en) 2024-03-28
US20190277858A1 (en) 2019-09-12

Similar Documents

Publication Publication Date Title
MA43377A (fr) Méthodes et compositions liées à la toxicité associée à la thérapie cellulaire
DK3307707T3 (da) Halogensubstituerede phenoxyphenylamidiner og anvendelsen deraf som fungicider
DK3421590T3 (da) Modificerede naturlige dræberceller og naturlige dræbercellelinjer med øget cytotoksicitet
DK3319428T3 (da) Herbicid sammensætning omfattende cinmethylin og imazamox
MA46959A (fr) Cellules b modifiées et compositions et méthodes associées
DK3355990T3 (da) Semifluorinerede forbindelser og disses sammensætninger
KR20180084891A (ko) 구조 조성물 및 방법
DK3145493T3 (da) Fremgangsmåder og sammensætninger vedrørende exosomer
DK3357513T3 (da) Farmaceutisk sammensætning og anvendelse deraf
DK3628161T3 (da) Synergistiske bakterielle sammensætninger og fremgangsmåder til fremstilling og anvendelse deraf
BR112017004648A2 (pt) simuladores mir-29 e os usos deste
DK3015526T3 (da) Hydrofluorolefinbaseret sammensætning og anvendelse deraf
MA41794A (fr) Agents thérapeutiques modifiés et compositions associées
BR112018000390A2 (pt) fenoxihalogenofenilamidinas e o uso dessas como fungicidas
DK3143011T3 (da) Deutererede heterocykliske forbindelser og deres anvendelse som billeddannende stoffer
DK3557998T3 (da) Sammensætninger, kompositioner og anvendelsesmetoder
DK3274430T3 (da) Mikroalgesammensætninger og deres anvendelser
DK3102200T3 (da) Terapeutisk forbindelse og sammensætning
DK3372232T3 (da) Tumorterapeutisk middel omfattende gemcitabinliposomsammensætning og kit
DK3242957T3 (da) Bakterieholdige sammensætninger og fremgangsmåder til anvendelse af samme til behandling og/eller forebyggelse af gastrointestinale, metaboliske og/eller andre sygdomme
DK3394131T3 (da) Strålehærdbare urethan(meth)acrylater med resterende isocyanatgrupper
DK3128005T3 (da) Sirp-alfa-variantkonstruktioner og anvendelser deraf
DK3261609T3 (da) Sammensætninger omfattende ravsyre og akonitsyre
DK3288379T3 (da) Peptidsammensætninger og anvendelsesmåder
DK3388085T3 (da) Farmaceutisk sammensætning og anvendelser deraf